Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Nat Methods ; 9(4): 345-50, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22453911

RESUMEN

The International Molecular Exchange (IMEx) consortium is an international collaboration between major public interaction data providers to share literature-curation efforts and make a nonredundant set of protein interactions available in a single search interface on a common website (http://www.imexconsortium.org/). Common curation rules have been developed, and a central registry is used to manage the selection of articles to enter into the dataset. We discuss the advantages of such a service to the user, our quality-control measures and our data-distribution practices.


Asunto(s)
Bases de Datos de Proteínas , Mapeo de Interacción de Proteínas , Proteínas/metabolismo , Publicaciones Periódicas como Asunto , Unión Proteica , Proteínas/química , Control de Calidad
2.
Expert Opin Ther Pat ; 30(7): 557-565, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32274944

RESUMEN

INTRODUCTION: Arenavirus are unique category-A pathogens that are also classified as Orphan diseases. Very few options exist currently for treating Viral Hemorrhagic Fever (VHF) caused by viruses belonging to the Arenaviridae family [1]. The current review provides detailed patent landscape and a description of selected technologies developed for combating category-A Arenavirus. Currently, Arenavirus infections are epidemic [2] but could cause widespread pandemics due to ease of dissemination and lack of immunity against these viruses. AREAS COVERED: The key strings for selected Arenavirus VHF were run separately in MCPaIRS®, PatSeer, and Questel database. The search was limited to Title, Abstract and Claim fields; one member per patent family was considered for analysis. EXPERT OPINION: Synthetic molecules dominate the patent landscape, while natural products have not been extensively claimed for the treatment of Arenavirus infection. The broad-spectrum activity has been highly desired for Arenavirus treatment, but few reports have experimentally tested it. With each year, a constant increase in number of patents published is seen, while the maximum number of applications was filed in 2017. The research in VHF is driven by public funds; the maximum numbers of patents were filed by publicly funded organizations.


Asunto(s)
Antivirales/farmacología , Infecciones por Arenaviridae/tratamiento farmacológico , Fiebres Hemorrágicas Virales/tratamiento farmacológico , Animales , Infecciones por Arenaviridae/virología , Arenavirus/aislamiento & purificación , Fiebres Hemorrágicas Virales/virología , Humanos , Patentes como Asunto , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/virología
3.
Pharmacol Rep ; 71(2): 374-383, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30851540

RESUMEN

Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs). This systematic review and meta-analysis, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, evaluated the efficacy, safety and tolerability of oxaceprol in OA. Electronic databases for published and grey (unpublished) literature were searched to identify parallel-group randomized controlled trials (RCTs) evaluating the impact of oxaceprol in patients with OA. Risk of bias was assessed using the Cochrane collaboration's tool. A total of seven parallel-group RCTs involving 1087 participants were included in the systematic review. Meta-analysis, in Review Manager, demonstrated numerically greater/significant improvements compared to active control [diclofenac/ibuprofen]/placebo in pain and function of joint; similar improvement vs. active control in global treatment efficacy; no difference/significant difference vs. active control/placebo in NSAIDs as rescue medication. Treatment with oxaceprol showed numerically less adverse events (AEs) than active control (diclofenac: risk ratio [RR], 0.71; 95% confidence interval [CI], 0.45 to 1.11; p=0.14: ibuprofen: RR, 0.73; 95% CI, 0.30 to 1.78; p=0.49) and significantly fewer AEs compared to placebo (RR, 0.76; 95% CI, 0.63 to 0.92; p=0.004). Given the nature of small-to-moderate sample size and short duration of eligible studies, the available clinical evidence of oxaceprol in the management of OA is modest - though looks promising. New and better RCTs with larger sample size and longer follow-up are warranted to strengthen the use of oxaceprol in clinical setting for managing OA.


Asunto(s)
Antirreumáticos/uso terapéutico , Hidroxiprolina/uso terapéutico , Osteoartritis/tratamiento farmacológico , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Antirreumáticos/efectos adversos , Diclofenaco/administración & dosificación , Diclofenaco/efectos adversos , Humanos , Hidroxiprolina/efectos adversos , Ibuprofeno/administración & dosificación , Ibuprofeno/efectos adversos , Osteoartritis/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Tamaño de la Muestra
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA